Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


CHMP positive for Jesduvroq to treat symptomatic anemia in adults with chronic kidney disease who are on dialysis – GSK

Written by | 7 Jul 2023 | Nephrology

Jesduvroq (daprodustat) from GSK received a positive opinion from the CHMP for the treatment of adult patients for for the treatment of symptomatic anaemia in adults with chronic kidney disease who are on chronic dialysis.

The benefit of Jesduvroq is its ability to correct haemoglobin levels in dialysis-dependent patients, with effects comparable to those seen with erythropoiesis-stimulating agents. The most common side effects are hypertension, thromboembolic events and diarrhoea.

Jesduvroq will be available as film-coated tablets. The active substance of Jesduvroq is daprodustat, an orally administered antianaemic (ATC code: B03XA07). Daprodustat inhibits hypoxia-inducible factor (HIF)-prolyl hydroxylase, thereby stimulating erythropoietin production. This increases iron mobilisation and the production of haemoglobin and red blood cells.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.